Recent advancements in the treatment of epithelial ovarian cancer

Journal of Obstetrics and Gynaecology Research

Volumn 27, Issue 2, 2001, Pages 61-75

  DiSaia, P J ^a   Tewari, K S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Management; Ovarian cancer

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALTRETAMINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; EPIRUBICIN; ETOPOFOS; GEMCITABINE; HYCAMPTIN; IMMUNOSTIMULATING AGENT; MELPHALAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; PLATINUM DERIVATIVE; PROTEIN P53; TAMOXIFEN CITRATE; TOPOTECAN; TRASTUZUMAB; TUBULIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BORDERLINE STATE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GYNECOLOGIC SURGERY; HUMAN; IMMUNOTHERAPY; LAPAROTOMY; LEUKOPENIA; METABOLIC DISORDER; NEUROTOXICITY; OVARY CANCER; PAIN; PRACTICE GUIDELINE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; REFRACTORY PERIOD; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; SUICIDE GENE; THEORY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034948525     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2001.tb01223.x     Document Type: Review

References (73)

1. Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy
2. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate
3. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
4. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma
5. Cisplatinum in the treatment of advanced or recurrent adenocarcinoma of the ovary: A phase II study of the Gynecologic Oncology Group
6. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: A Gynecologic Oncology Group Study
7. Randomized trial of cyclophosphamide and cis-platinum with or without doxorubicin in ovarian carcinoma: A gynecologic oncology group study
8. Chemotherapy for advanced ovarian cancer: Overview of randomized trials
9. Paper M-006
10. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
11. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma
12. Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer
13. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study
14. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
15. Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish Intergroup experience
16. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial
17. Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132
18. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
19. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials
20. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin
21. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
22. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynäekologische Onkologie (AGO) study group trial
23. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO/PAC) in optimal stage III epithelial ovarian cancer (OC)
24. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO/PAC) in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
25. Ovarian serous border-line tumors: A critical review of the literature with emphasis on prognostic indicators
26. Epithelial ovarian carcinoma: Principles of primary surgery
27. Long-term consequences following conservative management of epithelial ovarian cancer in an infertile patient
28. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer
29. Update on the role of radiotherapy in ovarian cancer
30. High-dose chemotherapeutic approaches to ovarian cancer management
31. Intraperitoneal therapy of ovarian cancer
32. Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study
33. Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support
34. Management of advanced ovarian cancer consensus summary
35. The Pastorian: A legacy of Louis Pasteur
36. The true history of the discovery of penicillin, with refutation of the misinformation in the literature
37. In vitro chemosensitivity testing and mechanisms of drug resistance in epithelial ovarian cancer
38. Responses to "salvage" chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population
39. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
40. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy
41. The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: Relevance to therapy and new drug testing
42. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
43. Chemotherapy of advanced ovarian cancer
44. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma
45. A multicenter phase II study of oxaliplatin (OXA) as a single agent in platinum (PT) and/or taxanes (TX) pretreated advanced ovarian cancer (AOC): Final results
46. Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer
47. Docetaxel for patients with ovarian cancer refractory to paclitaxel. An update
48. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
49. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
50. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients
51. Interaction between cisplatin and gemcitabine in vitro and in vivo
52. Phase I studies of gemcitabine combined with carboplatin or paclitaxel
53. Cisplatin (CDDP) & gemcitabine (DFDC) in relapsed ovarian cancer
54. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study
55. Phase 2 trial of chronic low dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer
56. A phase I study of paclitaxel, carboplatin, and increasing doses or prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: A Gynecologic Oncology Group study
57. Ovarian Cancer Meta-analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
58. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
59. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
60. Phase II study of high-dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin
61. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer
62. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
63. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody herceptin (H) in HER2-overexpressing (HER2 +) metastatic breast cancer (MBC)
64. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients
65. Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report
66. Tamoxifen in relapsed ovarian cancer: A systematic review
67. Follow-up of the asymptomatic patient with ovarian cancer
68. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study
69. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma
70. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
71. The prognostic significance of angiogenesis in epithelial ovarian carcinoma